Recent diabetes related articles in the Big 4

Access
BMJ - current paper copy in library, electronic access 3 months delay - NHS Athens
Lancet - electronic access 2 months delay - NHS Athens
JAMA - current electronic access - NHS Athens
NEJM - current paper copy in library, partial electronic access to recent articles - no password, full text electronic access - 3 months delay - NHS Athens

[NEWS] Major US consumer group asks FDA to ban drug for diabetes
BMJ current issue - Nov 5, 2008 (2 days ago)

LAB REPORTS: Diabetes and Bacteria
JAMA current issue - Nov 4, 2008 (3 days ago)

LAB, FIELD, & CLINIC: Adult Pancreatic Cells "Reprogrammed" Into Rarer Insulin-Producing Cells
JAMA current issue - Nov 4, 2008 (3 days ago)

COMMENTARY: Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes: Treating the Wrong Surrogate End Point?
JAMA current issue - Nov 4, 2008 (3 days ago)

[RESEARCH] Prevention of type 2 diabetes in British Bangladeshis: qualitative study of community, religious, and professional perspectives
...relation to diabetes prevention in the Bangladeshi community. Design Qualitative study (focus groups and semistructured interviews). Setting Tower Hamlets, a socioeconomically deprived London borough, United Kingdom. Participants Bangladeshi people without diabetes (phase 1), religious leaders and Islamic scholars (phase 2), and health professio...
BMJ current issue - Nov 4, 2008 (3 days ago)

[EDITORIALS] Preventing diabetes in Bangladeshi people in Britain
BMJ current issue - Nov 4, 2008 (3 days ago)

[Editorial] Rosiglitazone no longer recommended
...two leading diabetes societies. For the first time, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have issued guidelines that explicitly advise against the use of GSK's rosiglitazone for type-2 diabetes.
The Lancet - Oct 31, 2008 11:13 AM

ORIGINAL ARTICLE: GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes
...type 1 diabetes mellitus, would reverse recent-onset disease. C-peptide levels declined in both the treatment group and the control group, without significant between-group differences at month 15 (the primary end point), but they had declined significantly more slowly with treatment by month 30. The authors conclude that alum-formulated GAD may...
New England Journal of Medicine - Oct 29, 2008 9:30 PM

EDITORIAL: Immunotherapy on Trial for New-Onset Type 1 Diabetes
...Type 1 diabetes mellitus is an autoimmune disease in which pathologic, autoreactive T cells of the immune system attack the insulin-secreting pancreatic islets of Langerhans. Cytotoxic T cells, which bear ...
New England Journal of Medicine - Oct 29, 2008 9:30 PM

[PRACTICE] Request for slimming tablets
BMJ current issue - Oct 24, 2008 11:09 AM